image description

Press Releases

Press Releases

December 4, 2019
Revance Announces Pricing of Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)--Dec. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public
December 3, 2019
Revance Announces Proposed Public Offering of Common Stock
NEWARK, Calif. ,--(BUSINESS WIRE)--Dec. 3, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public
November 12, 2019
Revance to Participate in the Stifel 2019 Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel 2019 Healthcare Conference,
November 6, 2019
Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare
November 4, 2019
Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update
– Conference call and webcast today at 4:30 p.m. ET – NEWARK, Calif. --(BUSINESS WIRE)--Nov. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the
Displaying 1 - 10 of 188